Research Reports

Key takeaways

Maria Rivas appointed as Non-Executive Director; she brings 25+ years of pharmaceutical experience and previously served as Pfizer's Chief Medical Officer.

William Jellison appointed as Non-Executive Director; he has 30+ years of corporate finance experience and previously served as CFO of Stryker Corporation.

Both appointments are effective May 11, 2026, subject to the grant of Australian Director Identification numbers.

The appointments are part of a Board expansion and succession planning initiative aligned with Telix's evolution as a dual-listed, global commercial-stage company.

Interim Chair Dr. Mark Nelson highlighted the appointees' experience in U.S. public company governance and financial oversight as significantly enhancing Board capability.

Full analysis

Telix Pharmaceuticals is strengthening its Board of Directors with two high-profile appointments effective May 11, 2026. Dr. Maria Rivas brings extensive clinical and governance experience, having served as Chief Medical Officer at Pfizer and currently sitting on the board of The Cooper Companies. Her background in late-stage clinical development and commercialization across oncology and rare diseases aligns with Telix's strategic focus. William Jellison contributes deep financial and audit committee expertise, having served as CFO of Stryker Corporation and currently holding board positions at Medtronic and Anika Therapeutics. Interim Chair Dr. Mark Nelson emphasized that these appointments, alongside the recent addition of David Gill, enhance the Board's U.S. public company governance and financial oversight capabilities, supporting Telix's transition to a dual-listed, global commercial-stage biopharmaceutical company.

TLPPF · Telix Pharmaceuticals Limited

Summary

Key takeaways

Full analysis